Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Our hypothesis is that IV or SQ Treprostinil can improve 6 minute walk distance, hemodynamics
and quality of life in patients with interstitial lung disease and severe secondary pulmonary
arterial hypertension.
Phase:
Phase 2
Details
Lead Sponsor:
Rajan Saggar University of California, Los Angeles